| Course | NURS 6521 Advanced Pharmacology |
|---|---|
| Week | Week 11 |
| Paper type | Multisystem prescribing synthesis |
| Length | About 1,160 words, 7 pages |
| Format | APA 7 student paper |
| School | Walden University |
| Program | Master of Science in Nursing (MSN) |
| Updated | October 2026 |
Free sample paper for NURS 6521 Week 11
One Regimen for Three Conditions: Hypertension, Asthma, and Depression in a 46-Year-Old Woman Who Is a CYP2C19 Poor Metabolizer
Student Name
College of Nursing, Walden University
NURS 6521: Advanced Pharmacology
Instructor Name
Month Day, Year
One Regimen for Three Conditions: Hypertension, Asthma, and Depression in a 46-Year-Old Woman Who Is a CYP2C19 Poor Metabolizer
Patient Summary
The patient is a composite prepared for this assignment. Ms. N.C. is a 46-year-old paralegal with three active conditions. Hypertension was diagnosed five years ago and is treated with metoprolol tartrate 50 mg twice daily, started by a previous clinician; her home average is 142/90. Moderate persistent asthma is treated with budesonide-formoterol 160/4.5 mcg, two inhalations twice daily, with albuterol as needed; over the past year she has needed albuterol more often and says it "doesn't work as well as it used to." Major depressive disorder, moderate, recurred four months ago after a divorce. Two years ago she stopped escitalopram 10 mg after three weeks because of nausea, dizziness, and a racing heart. A pharmacogenomic panel ordered at that time reports that she is a CYP2C19 poor metabolizer (*2/*2) and a CYP2D6 normal metabolizer. She has no drug allergies. Her kidney and liver function are normal, and a recent electrocardiogram showed sinus rhythm with a corrected QT of 438 ms.
Hypertension
Her blood pressure is above target on metoprolol, and the beta blocker is the wrong agent for her for two reasons that belong to her other conditions. Metoprolol is beta-1 selective, but selectivity is relative and falls with dose. Albuterol and formoterol relieve bronchospasm through beta-2 receptors, and even a selective beta blocker can blunt that response and worsen airway function in some patients; a meta-analysis of randomized trials found that acute exposure to cardioselective beta blockers produced a small mean fall in FEV1 and attenuated the response to beta-agonists, with larger effects from nonselective agents (Morales et al., 2014). Her report that albuterol works less well is consistent with that. Beta blockers are also not preferred first-line agents for uncomplicated hypertension without a compelling indication such as heart failure or coronary disease (Carey et al., 2022). A nonselective agent such as propranolol would be worse still, since blocking beta-2 receptors directly opposes bronchodilation.
The plan replaces metoprolol with amlodipine 5 mg daily, a dihydropyridine calcium channel blocker that lowers peripheral resistance by preventing calcium entry into arteriolar muscle cells and has no effect on airway receptors. Metoprolol is tapered over one to two weeks rather than stopped abruptly, to avoid rebound tachycardia and hypertension. A thiazide would also be reasonable, and it remains the add-on if amlodipine alone does not reach target.
Against the remaining agents: amlodipine does not interact with budesonide, formoterol, or albuterol, and it is not meaningfully affected by the antidepressant chosen below. Removing metoprolol also removes a CYP2D6 substrate from her list, which becomes important in the depression section.
Asthma
Her controller regimen follows current guidance: budesonide-formoterol maintenance at a medium inhaled corticosteroid dose, with a reliever (Global Initiative for Asthma [GINA], 2024). Before any step up, three things are checked, because her worsening control may have causes other than the asthma itself. Inhaler technique is observed. Adherence is reviewed, since depression often reduces it. And the beta blocker, a medication that can blunt bronchodilator response, is removed, as above. The plan also simplifies her reliever: GINA's preferred approach uses the same budesonide-formoterol inhaler as needed for symptoms instead of albuterol, so that each reliever dose also delivers anti-inflammatory treatment. She is switched to that approach and albuterol is kept only as a backup until she is comfortable with it.
Against the remaining agents: inhaled budesonide has little systemic exposure at this dose and no clinically important interaction with amlodipine or bupropion. Formoterol, a beta-2 agonist, can raise heart rate and lower potassium slightly; neither is a concern with amlodipine, and removing metoprolol means formoterol no longer works against a beta blocker.
Depression
The pharmacogenomic result explains her history. Escitalopram is metabolized mainly by CYP2C19. As a poor metabolizer with two nonfunctional alleles, she clears it much more slowly than most patients, so a standard 10 mg dose produced drug exposure well above the usual range, and the nausea, dizziness, and tachycardia she experienced are consistent with that excess. The Clinical Pharmacogenetics Implementation Consortium turns genotype into a prescribing action: for CYP2C19 poor metabolizers, it recommends considering an antidepressant not predominantly metabolized by CYP2C19, or, if citalopram, escitalopram, or sertraline is used, starting at a reduced dose and titrating slowly (Bousman et al., 2023).
Two paths were considered. A reduced dose of sertraline would follow the guideline but would leave her dependent on the same impaired pathway after a bad experience with a drug in that group, which may also affect her willingness to take it. Choosing an agent that does not depend on CYP2C19 avoids the problem. The plan selects bupropion extended-release, 150 mg each morning, increased to 300 mg after at least a week if tolerated. Bupropion inhibits reuptake of norepinephrine and dopamine and is metabolized mainly by CYP2B6, not CYP2C19, so her poor-metabolizer status does not affect it. It tends to cause less nausea and less sexual dysfunction than SSRIs and does not cause weight gain. Its main risk is a dose-related reduction in the seizure threshold, and she has no seizure history, eating disorder, or heavy alcohol use, the conditions that would contraindicate it.
Against the remaining agents: bupropion is a strong inhibitor of CYP2D6. Had metoprolol, a CYP2D6 substrate, remained on her list, bupropion would have raised metoprolol concentrations, increasing the risk of bradycardia and further beta blockade in her airways. The hypertension decision already removed that interaction. Amlodipine is metabolized by CYP3A4 and is unaffected. Bupropion has no clinically important interaction with inhaled budesonide or formoterol, and it does not prolong the QT interval meaningfully at usual doses.
Final Interaction Screen
The complete revised list, amlodipine, budesonide-formoterol maintenance and reliever, albuterol as backup, and bupropion extended-release, was checked one combination at a time, and nothing rated contraindicated or major came back. The metoprolol and bupropion interaction, which would have been major, is avoided by the regimen's design. Monitoring is set for each condition: home blood pressure readings weekly and a review at four weeks; asthma control questions and inhaler technique at the same visit; and depression symptoms with the PHQ-9 at four and eight weeks, with specific questions about insomnia, agitation, and suicidal thoughts in the first weeks of bupropion.
Summary Table
Amlodipine 5 mg daily: hypertension. Rationale: lowers vascular resistance without airway effects; replaces metoprolol, which blunted her beta-agonist response and would have interacted with bupropion.
Metoprolol tartrate: discontinued by taper over one to two weeks. Rationale: beta blockade in a patient with asthma; no compelling cardiac indication; CYP2D6 substrate.
Budesonide-formoterol 160/4.5 mcg, two inhalations twice daily and one as needed: asthma. Rationale: guideline controller and reliever; each reliever dose adds anti-inflammatory therapy.
Albuterol as needed: backup reliever only during the transition.
Bupropion XL 150 mg each morning, then 300 mg: depression. Rationale: not dependent on CYP2C19, avoiding the pathway that caused her escitalopram intolerance; no weight gain or sexual dysfunction; CYP2D6 inhibition made safe by removing metoprolol.
References
Bousman, C. A., Stevenson, J. M., Ramsey, L. B., Sangkuhl, K., Hicks, J. K., Strawn, J. R., Singh, A. B., Ruaño, G., Mueller, D. J., Tsermpini, E. E., Brown, J. T., Bell, G. C., Leeder, J. S., Gaedigk, A., Scott, S. A., Klein, T. E., Caudle, K. E., & Bishop, J. R. (2023). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clinical Pharmacology & Therapeutics, 114(1), 51-68. https://doi.org/10.1002/cpt.2903
Carey, R. M., Moran, A. E., & Whelton, P. K. (2022). Treatment of hypertension: A review. JAMA, 328(18), 1849-1861. https://doi.org/10.1001/jama.2022.19590
Global Initiative for Asthma. (2024). Global strategy for asthma management and prevention. https://ginasthma.org/2024-report/
Morales, D. R., Jackson, C., Lipworth, B. J., Donnan, P. T., & Guthrie, B. (2014). Adverse respiratory effect of acute beta-blocker exposure in asthma: A systematic review and meta-analysis of randomized controlled trials. Chest, 145(4), 779-786. https://doi.org/10.1378/chest.13-1235
NURS 6521 Week 11 instructions, in plain terms
The final NURS 6521 week asks you to prescribe for a patient with several conditions at once. Review each condition, choose therapy that works across all of them, address interactions and pharmacogenomics, run a final screen and summarize. Integration earns the largest share, so three short analyses joined together lose it. Cite guidelines and CPIC recommendations in APA 7. Not every final case includes a genetic result, but when one is given it should shape the choice. Leaving a regimen unchanged can be right when the problem is technique or adherence. The patient is a composite. Give each condition a short section that names its effect on the others, then close with the final screen and a summary table of every drug, its purpose and its monitoring.
How the NURS 6521 Week 11 example is put together
Six pages. A patient summary lists her diagnoses, current agents, allergy history and a pharmacogenomic report showing she metabolizes certain antidepressants poorly through one hepatic enzyme. A section per condition follows. The hypertension section keeps her on a class that does not threaten her airways and explains why a nonselective beta blocker would. The asthma section confirms her controller regimen and checks it against everything else. The depression section is the longest: it reads the genotype through Clinical Pharmacogenetics Implementation Consortium guidance, cited for its central idea of turning a genotype into a prescribing action, and chooses an antidepressant that does not depend on the affected enzyme. A final interaction check screens the complete list, and a one-page summary table shows every agent, its indication and its rationale.
NURS 6521 Week 11 rubric: what earns full marks
Integration earns the largest share on most closing rubrics here, and it is lost when three conditions are treated as three short analyses stapled together. A regimen whose parts were never checked against each other reads that way at once. Pharmacogenomic reasoning often carries its own criterion, and it is marked on application: explaining what poor metabolism means in general earns less than showing how it changed the antidepressant choice. Mechanism accuracy is assessed across all three conditions, so an error in the least developed section costs as much as one in the most developed. The final screen and summary table are marked for completeness. Evidence from current guidelines, cited specifically, completes the content score.
NURS 6521 Week 11 help from the desk
Final syntheses score poorly when each condition is treated alone. Show how each choice affects the others. A second weakness is ignoring the genetic result. Use CPIC guidance. Writers also skip the final screen. Run it. Avoid adding drugs before checking adherence and technique. Ask first. Summarize in a table. A sentence explaining that her poor CYP2C19 status raised escitalopram levels and likely caused her side effects links the past to the new choice. Close with the follow-up plan for all three conditions. Check the summary table against each section before submitting.
Get a NURS 6521 Week 11 example written to your instructions
Final cases differ widely between terms, so the sample is built on the patient in your prompt, with every condition and test result it lists. Send that with the rubric. The Week 11 synthesis is returned in 24 to 48 hours and the first custom one is free. Where no genotype appears in your case, that section is omitted rather than invented.
More NURS 6521 papers and MSN samples
- NURS 6521 Week 1: Adverse Drug Event Review
- NURS 6521 Week 2: Prescriptive Authority Analysis
- NURS 6521 Week 3: Cardiovascular Drug Therapy Plan
- NURS 6521 Week 4: Stepwise Inhaler Therapy Post
- NURS 6521 Week 5: Antidiabetic Selection Brief
- NURS 6521 Week 6: Gastrointestinal Agent Analysis
- NURS 6521 Week 7: Neurologic Prescribing Tree
- NURS 6521 Week 8: Hormonal Agent Risk Post
- NURS 6521 Week 9: Antimicrobial Stewardship Rationale
- NURS 6521 Week 10: Drug Interaction Screening Report
- NURS 6630 Week 11: Reflection
- NURS 6512 Week 11: Full-System History and Physical
- NURS 6710 Week 11: Reflection
- NURS 6501 Week 11: Multisystem Cascade Synthesis
NURS 6521 Week 11 questions, answered
Does every final case include a pharmacogenomic result?
No, and the example includes one because it lets the synthesis show a factor the course introduces early and rarely returns to. If your case has no genetic information, the synthesis gives that space to another patient factor, such as kidney function, pregnancy potential or adherence, and applies it across all conditions in the same way.
Why is the asthma regimen left unchanged?
Because a synthesis that changes everything can look like activity rather than judgment. Her controller therapy was working, and the rationale shows it was deliberately rechecked against the new agents and kept. Rubrics in this area often credit a documented decision to continue as highly as a decision to change, provided the reasoning is written out.
Is the patient with three conditions real?
She is invented. Hypertension, asthma and depression were combined because each choice constrains the others, and a genotype was added to give the depression section a concrete factor to apply. No chart was used. Your own synthesis should work only from the case your course assigns, adding nothing the prompt does not supply.
Where can I find a free NURS 6521 Week 11 sample paper?
The three-condition regimen synthesis is printed here with hypertension, asthma and depression plans, the final interaction screen and the summary table.
Why replace metoprolol in NURS 6521 Week 11?
Beta blockers can worsen asthma, and her albuterol use is rising, so a different antihypertensive fits all three conditions better.